International market entry specialists – GBT Pharma – have been appointed by Iscador Ltd to build international presence for its anthroposophic mistletoe preparation, Iscador.
Iscador is a prescription only drug formulated using specific mistletoe extracts, used for the adjuvant treatment of tumorous diseases in the field of integrative oncology.
GBT Pharma’s brief is to take over the existing business, build the infrastructure and grow global distribution.
In ancient times mistletoe was renowned for its medicinal properties and used to treat a wide range of ailments. For almost one hundred years it has also been applied in anthroposophic cancer therapy.
Iscador, and its use in cancer treatment first became a possibility in 1907 when philosopher Rudolf Steiner founded the Anthroposophical movement, which led to many innovations in pharmaceutical and therapeutic concepts. Notably in 1917, Dr. Ita Wegman used a mistletoe extract to treat a cancer patient for the very first time.
Anthroposophic mistletoe preparations are produced by a special blending process of extracts from mistletoes, harvested in summer and winter to ensure the extraction of specific seasonal properties of the plant. The preparations comprise total extracts of the mistletoe and a complex range of agents.
Iscador Ltd was founded on the work of the Hiscia Institute where mistletoe preparations have been produced for more than six decades. As part of their mission to develop pharmaceuticals for oncological use, Iscador undertakes significant research in the field of mistletoe and cancer.
GBT Pharma has a proven portfolio in facilitating new market access for consumer healthcare companies across the globe.
GBT Pharma founder Gian Trepp comments: “We are delighted to be working with this historic brand which has been instrumental in pioneering knowledge of the use of mistletoe extracts in the adjuvant treatment of cancer.
“Our mission is to identify and secure suitable partners to distribute this innovative therapy across the world. Our first target will be the Swiss market, before widening our approach to cover the worldwide markets.”
For further information please contact us